Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
L3Harris
LHX
|
+$154M |
| 2 |
GE HealthCare
GEHC
|
+$103M |
| 3 |
Atlassian
TEAM
|
+$94.5M |
| 4 |
AXON
Axon Enterprise
AXON
|
+$21M |
| 5 |
Reliance Steel & Aluminium
RS
|
+$20.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$322M |
| 2 |
Microsoft
MSFT
|
+$176M |
| 3 |
GE Aerospace
GE
|
+$115M |
| 4 |
Amazon
AMZN
|
+$79.9M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$77.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.64% |
| 2 | Healthcare | 14.81% |
| 3 | Consumer Discretionary | 11.76% |
| 4 | Industrials | 9.45% |
| 5 | Communication Services | 8.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PSTX
2601
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $314K | ﹤0.01% |
+102,100
| New | +$612K |
|
|
LBC
2602
DELISTED
Luther Burbank Corporation Common Stock
LBC
| $314K | ﹤0.01% |
33,100
-3,900
| -11% | -$43.2K |
|
|
SNPO
2603
DELISTED
Snap One Holdings Corp. Common Stock
SNPO
| $307K | ﹤0.01% |
32,800
-3,100
| -9% | -$30.6K |
|
|
NYAX
2604
Nayax
NYAX
$1.86B
| $303K | ﹤0.01% |
17,890
-1,579
| -8% | -$30.7K |
|
2605
Cullinan Oncology
CGEM
$1.26B
| $303K | ﹤0.01% |
29,600
-3,400
| -10% | -$37.5K |
|
2606
BRC Inc
BRCC
$215M
| $303K | ﹤0.01% |
58,900
-2,500
| -4% | -$15.7K |
|
|
IGMS
2607
DELISTED
IGM Biosciences
IGMS
| $302K | ﹤0.01% |
22,000
-2,500
| -10% | -$51.7K |
|
|
WE
2608
DELISTED
WeWork Inc.
WE
| $297K | ﹤0.01% |
9,550
-1,155
| -11% | -$63.1K |
|
2609
Atlanticus Holdings
ATLC
$1.48B
| $296K | ﹤0.01% |
10,900
-1,600
| -13% | -$48.1K |
|
2610
Amneal Pharmaceuticals
AMRX
$6.15B
| $295K | ﹤0.01% |
212,500
-25,100
| -11% | -$50K |
|
2611
Latham Group
SWIM
$921M
| $289K | ﹤0.01% |
101,100
-12,300
| -11% | -$43.2K |
|
2612
Phathom Pharmaceuticals
PHAT
$742M
| $288K | ﹤0.01% |
40,400
-1,100
| -3% | -$9.66K |
|
|
MMAT
2613
DELISTED
Meta Materials Inc. Common Stock
MMAT
| $287K | ﹤0.01% |
7,031
-810
| -10% | -$62.9K |
|
2614
Nektar Therapeutics
NKTR
$2.57B
| $285K | ﹤0.01% |
27,047
-3,120
| -10% | -$94.4K |
|
2615
Stoke Therapeutics
STOK
$2.13B
| $284K | ﹤0.01% |
34,100
-3,100
| -8% | -$28K |
|
|
BHIL
2616
DELISTED
Benson Hill, Inc.
BHIL
| $282K | ﹤0.01% |
7,003
-800
| -10% | -$59.7K |
|
|
AEVA
2617
Aeva Technologies
AEVA
$1.75B
| $280K | ﹤0.01% |
47,120
-3,740
| -7% | -$30K |
|
2618
Holley
HLLY
$384M
| $280K | ﹤0.01% |
102,100
-11,800
| -10% | -$30.2K |
|
|
ESPR
2619
DELISTED
Esperion Therapeutics
ESPR
| $274K | ﹤0.01% |
172,500
+35,900
| +26% | +$185K |
|
|
VLD
2620
DELISTED
Velo3D, Inc.
VLD
| $274K | ﹤0.01% |
3,449
-260
| -7% | -$23.3K |
|
2621
Advantage Solutions
ADV
$399M
| $273K | ﹤0.01% |
6,900
-604
| -8% | -$34.1K |
|
2622
Organogenesis Holdings
ORGO
$233M
| $271K | ﹤0.01% |
127,100
-9,300
| -7% | -$23K |
|
|
CRGE
2623
DELISTED
Charge Enterprises, Inc. Common Stock
CRGE
| $270K | ﹤0.01% |
245,295
-28,500
| -10% | -$35.9K |
|
|
HA
2624
DELISTED
Hawaiian Holdings, Inc.
HA
| $254K | ﹤0.01% |
27,709
-2,600
| -9% | -$27.5K |
|
|
NGM
2625
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $252K | ﹤0.01% |
61,700
-4,100
| -6% | -$18.9K |
|
Similar funds
Swiss National Bank's Q1 2023 Portfolio in Review
As of Q1 2023, Swiss National Bank held 2,715 positions worth $146B, up 4.7% from $139B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Swiss National Bank withdrew a net $4.63B in Q1 2023, closing 72 positions and reducing 2,517 holdings. Its most notable exit was STORE Capital Corporation, an estimated $19.7M position sold in full.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Swiss National Bank opened a new position in L3Harris worth $148M.
- Swiss National Bank's largest Q1 2023 buy was L3Harris: 754,729 shares worth $148M.
- Swiss National Bank added most to Axon Enterprise in Q1 2023, an estimated $21M increase.
- Swiss National Bank's biggest Q1 2023 reduction was Apple, cutting an estimated $322M.
- Swiss National Bank fully exited STORE Capital Corporation in Q1 2023, selling an estimated $19.7M.
- Swiss National Bank's ten largest holdings make up 26% of its $146B portfolio in Q1 2023.
- Swiss National Bank opened 37 new positions and closed 72 in Q1 2023.
- Swiss National Bank's portfolio value rose 4.7% quarter-over-quarter to $146B.
Based on Swiss National Bank's 13F filing for Q1 2023, filed 10 May 2023.